HAOHAI BIOTEC (06826) · Company profile · Eqvero

HAOHAI BIOTEC

06826HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	2.45 bn CNY	2.68 bn CNY	2.63 bn CNY	2.1 bn CNY	1.75 bn CNY
Cost of revenue	550.03 m CNY	637.89 m CNY	583.55 m CNY	452.3 m CNY	327.53 m CNY
Research and development expense	220 m CNY	260.79 m CNY	241.61 m CNY	206.28 m CNY	185.29 m CNY
Selling, general and administrative expense	1.25 bn CNY	1.23 bn CNY	1.24 bn CNY	1.08 bn CNY	898.43 m CNY
Operating profit after depreciation	239.23 m CNY	372.03 m CNY	398.53 m CNY	164.38 m CNY	196.9 m CNY
Operating profit before depreciation	445.99 m CNY	577.25 m CNY	596.39 m CNY	368.6 m CNY	359.73 m CNY
EBIT	239.23 m CNY	372.03 m CNY	398.53 m CNY	164.38 m CNY	196.9 m CNY
EBITDA	445.99 m CNY	577.25 m CNY	596.39 m CNY	368.6 m CNY	359.73 m CNY
Interest expense	18.88 m CNY	18.06 m CNY	7.3 m CNY	7.6 m CNY	4.96 m CNY
Profit before tax	239.25 m CNY	466.15 m CNY	508.26 m CNY	235.73 m CNY	382.65 m CNY
Income tax expense	30.92 m CNY	89.9 m CNY	95.99 m CNY	45.4 m CNY	35.37 m CNY
Income before extraordinary items	251.01 m CNY	420.45 m CNY	416.12 m CNY	180.47 m CNY	352.23 m CNY
Common dividends	227.17 m CNY	230.93 m CNY	166.83 m CNY	68.51 m CNY	123.08 m CNY
Total dividends	227.17 m CNY	230.93 m CNY	166.83 m CNY	68.51 m CNY	123.08 m CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.